Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial
Nature Medicine, Published online: 22 September 2026; doi:10.1038/s41591-026-04679-x In a phase 1b/2 trial, first-line treatment of participants with biliary tract cancer with human epidermal growth factor receptor 2 (HER2)-targeting trastuzumab in combination with nivolumab plus gemcitabine and cisplatin showed encouraging clinical response rates and HER2 expression was associated with clinical…
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
